LIVE NOW: Miracle Riders announce plans for 2025 miracle ride
COLUMBUS, Ga. () — Charity group the Miracle Riders are hosting a news conference to announce their plans for the dates and theme for the 2025 Miracle Ride supporting the Columbus State University's Nursing School.
Watch the conference live in the video player above.
Speakers for the event include
CSU President Dr. Stuart Rayfield,
Dr. Margie Yates, Dean,
CSU College of Education and Health Professions,
Scott Ressmeyer,
Co-owner of Country's Barbecue, and the Miracle Riders, David Levine, M.D., Neonatology Associates of Columbus
The Miracle Riders have supported the CSU School of Nursing since 2021, when they established a multi-year fundraising goal of $1 million to enhance the school's pediatric nursing program.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
12 hours ago
- CBS News
University of California researchers face uncertain future over possible federal funding cuts
Thousands of University of California and California State University system workers are unsure about their jobs and the future of their research after reports that President Donald Trump is going after the federal funding for California. In response, Gov. Gavin Newsom has threatened to stop paying the state's federal taxes. Tanzil Chowdhury is a graduate student researcher at UC Berkeley with the Materials Science and Engineering Department. He works on semiconductors and is researching how to create more efficient batteries and better solar panels. His academic future, however, is in limbo. "I really want to make a difference with the work that I do, I want to help transition off of fossil fuels and create greener and more efficient energy grid for everyone. With these cuts, I don't know if I'll be able to continue doing that," Chowdhury told CBS News Bay Area. That's because Mr. Trump is considering pulling funding for both the UC and Cal State University systems. "This would just be catastrophic to my work, the work of all my coworkers and the amazing research that happens here in the state of California at the UC and CSU," he said. "We can't access the materials that we need, we can't get the lab space that we need, we can't run our experiments if there's no money coming in." A recent report shows the UC system received more than $4 billion for academic research during the 2024 fiscal year. Schools, including UC San Francisco, rely on those grants. "This is one of the biggest recipients of National Institute of Health's funds, which are some of the funds that the Trump administration is reportedly going to cut," Chowdhury said. He helps lead UAW Local 4811, a union of 48,000 academic workers in the UC system. Chowdhury said about 15,000 of those academic workers are from UC San Francisco and UC Berkeley. "It is one of the nation's leaders in biomedical and biological research. So, groundbreaking treatments in cancer, heart disease, diabetes, all that stuff happens right here," he said. "The patient who needs that sort of groundbreaking research to get better, get healthier, that work stops." One infectious disease doctor and UC San Francisco professor agrees. "We receive 30% of all NIH funding in this country. And that's not because just that we are a more populous state, but because we have fantastic universities here, really high-level academics," Dr. Monica Gandhi told CBS News Bay Area. She added that funding cuts will have a dire impact on the patient level. "It would mean the complete slowing of any progress in biomedical research that is actually fueling American lives, health," she added. "People who are living in California, their health will absolutely be affected. We won't get novel medications, we won't get therapeutics for cancer, for diabetes, for HIV, for infectious diseases." Dr. Gandhi said that a recent analysis showed that three out of 365 medications that had been approved from 2010 to 2019 were from NIH-funded research. "It would be disastrous for California to not be able to continue the lifesaving, NIH-funded research that it does," she added. Meanwhile, Chowdhury hopes that Governor Gavin Newsom can help by rescinding academic budget cuts on the state level. "He should work with the California legislature to ensure that we have job security, and we're able to continue doing the research that we need to do, and fill in the gaps left behind by the federal government," Chowdhury said. While the future remains uncertain, the battle for academia continues. "The administration needs to not do this, because we don't want to mess with American lives and American health," Dr. Gandhi said. "Maybe we need to re-evaluate how much money we give to the federal government from California taxpayer dollars, because I know what my California taxpayer dollars to go to. I want them to go to life-saving medical research to extend human life," she added.
Yahoo
5 days ago
- Yahoo
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in cold urticaria (ColdU) or symptomatic dermographism (SD) during an oral session on Saturday, June 14. Details of the presentations are as follows: Abstract Title: Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H-1 Antihistamine TreatmentAbstract Number: 269Session Type/Title: Oral Abstract Session on Clinical Trials (OAS-CT2, Clinical Trials on Dermatology) Presentation Date/Time: June 14, 3:00-4:30pm Abstract Title: A Single Dose of Briquilimab, an Anti-Human c-Kit (CD117)-Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117Abstract Number: 523Session Type/Title: Thematic Poster Session (Biologicals 02)Presentation Date/Time: June 14, 12:00-1:00pm Abstract Title: Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from Phase 1b/2a StudyAbstract Number: 100281Session Type/Title: Flash Talk (L-FT08 Dermatology) Presentation Date/Time: June 15, 12:45-1:45pm Abstract Title: Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117)-Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 MiceAbstract Number: 537Session Type/Title: Thematic Poster Session (Asthma 07),Presentation Date/Time: June 15, 12:45-1:45pm About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper's presentations at the EAACI Annual Congress. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Yahoo
2025 hurricane season starts: This year's outlook, how Florida residents can prepare
The Brief The 2025 Atlantic hurricane season starts June 1, with NOAA and CSU predicting above-average activity due to warm oceans and favorable conditions. Forecasts call for up to 19 named storms, 10 hurricanes, and 5 major hurricanes. How likely will a hurricane or tropical storm make landfall in the U.S. this year? CSU explains. ORLANDO, Fla. - The 2025 Atlantic hurricane season officially begins on June 1, and much like last year, the FOX 35 Storm Team expects a lot of ocean heat content to fuel the potential for an above-average season. Experts at both the National Oceanic and Atmospheric Administration (NOAA) and Colorado State University (CSU) share a similar outlook: What we know NOAA's hurricane forecast: 13-19 named storms 6-10 hurricanes 3-5 major hurricanes (Cat. 3 or higher) CSU's hurricane forecast: 17 named tropical storms Of which, 9 become hurricanes Of which, 4 reach "major" hurricane strength (Cat. 3 or higher) Big picture view According to the NOAA Climate Prediction Center, an average Atlantic hurricane season sees: 14 named tropical storms 7 hurricanes 3 "major" hurricanes (Category 3 or higher) Dig deeper There are a multitude of factors in the atmosphere that will heighten the chance of an above-average season. The climate pattern has been shifting, and it's looking like we're going to remain in the Neutral Phase of ENSO. With that, we typically see reduced wind shear in the Atlantic Basin which means storms can form and strengthen rapidly. That strengthening is only exacerbated by the warmer than average ocean temperatures. That along with more active Western African Monsoon can help spin-up more tropical systems. Colorado State University also looks at the probability of whether a "major" hurricane – Category 3, 4, or 5 storm – will make landfall in the U.S., along Florida's Coast, or within the Gulf Coast. 51% for the entire U.S. coastline (average from 1880–2020 is 43%). 26% for the U.S. East Coast, including the Florida peninsula (average from 1880–2020 is 21%). 33% for the Gulf Coast from the Florida panhandle westward to Brownsville, Texas(average from 1880–2020 is 27%). 56% for the Caribbean (average from 1880–2020 is 47%) Here are the tropical cyclone names for the 2025 Atlantic hurricane season. Click here to view the pronunciation guide. Andrea Barry Chantal Dexter Erin Fernand Gabrielle Humberto Imelda Jerry Karen Lorenzo Melissa Nestor Olga Pablo Rebekah Sebastien Tanya Van Wendy It's never too early to prepare for the upcoming hurricane season – or any emergency. It's important to have a plan, have ways to communicate and get emergency information, save and protect important documents, medication, and have extra food and water. Click the links below for helpful guides on what to pack in your emergency kit: Florida Disaster Supply Kit Checklist emergency kit Here are a few other key ways to prepare for hurricane season in Florida: Know your evacuation zone and route by checking Stay informed by downloading weather apps, signing up for local alerts, and monitoring trusted news sources. Plan for pets and vulnerable family members, including elderly relatives or those with medical needs. Back up important digital files and contacts in case of power outages or loss of access. The FOX 35 Storm Team and newsroom will be with you every step of the way during hurricane season. Download the free FOX Local app to your smart phone for the latest breaking news, weather updates, and tropical forecasts. Download the FOX 35 Weather app to track the latest weather forecasts and tropical cones on your cell phone. Install the FOX Local app to your smart TV to stream FOX 35 newscasts. STAY CONNECTED WITH FOX 35 ORLANDO: Download the FOX Local app for breaking news alerts, the latest news headlines Download the FOX 35 Storm Team Weather app for weather alerts & radar Sign up for FOX 35's daily newsletter for the latest morning headlines FOX Local:Stream FOX 35 newscasts, FOX 35 News+, Central Florida Eats on your smart TV The Source This story was written based on information shared by the FOX 35 Storm Team on June 1, 2025.
